Corporate Member Merck - EXPANDED INDICATION

Corporate Member Merck - EXPANDED INDICATION

KEYTRUDA (Pembrolizumab)
April, 2018

KEYTRUDA is indicated for the first-line treatment of patients with metastatic non–small cell lung cancer (mNSCLC) whose tumors have high PD-L1 expression [tumor proportion score (TPS) ≥50%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members